Portfolio Companies

Our growing portfolio of joint venture companies pursuing AI-based drug discovery with the Atomwise discovery engine provides new opportunities for licensing and investment.

Fueling Innovation with AI-based Drug Discovery

The synergy of the biology exploration by our partners and chemical exploration with our AtomNetĀ® technology creates discoveries that will advance therapies for disease areas with unmet needs.

A2i Therapeutics
A2i Therapeutics is a joint venture with FutuRx developing novel small molecule agents for immuno-oncology, funded by J&J, Takeda Ventures, OrbiMed, Leaps by Bayer and the Israeli Innovation Authority.
OrganAi seeks to develop novel drugs for rare diseases by leveraging our AtomNetĀ® technology and StemoniX's clinically translatable human iPSC-derived neurospheroids in high-throughput format.
The Atomwise-Velocity Pharmaceutical Development joint venture has initiated five development programs in areas of high medical need including cancer, autoimmune diseases, and clotting disorders.
View our co-developed pipeline

Interested in Our Portfolio Companies?

Contact us to invest in or license from our portfolio companies.

Contact Us